Pulse nav.journalClub Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

August 19, 2009Open Access

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.

Leer artículo completoexternamente

Me gusta

Guardar

Compartir

Ver artículo completo

Me gusta

Guardar

Compartir

Ver artículo completo

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer | Synapse

Cite This Study

Rosell et al. (Wed,) studied this question.

synapsesocial.com/papers/69da11319a6164e50fa3db8b https://doi.org/https://doi.org/10.1056/nejmoa0904554

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib2006 · 584 citations
2Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers2007 · 164 citations
3Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors2006 · 486 citations
4Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib2006 · 742 citations
5Situación del cáncer en España: incidencia2004 · 90 citations